Text Size
30 studies found for:    Open Studies | "beta-Thalassemia"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "beta-Thalassemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown † Beta-thalassemia and Microparticles
Conditions: Thalassemia Major (TM);   Thalassemia Intermedia (TI);   Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes
Intervention: Other: Physiopathology
2 Recruiting Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Mozobil
3 Not yet recruiting A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects
Condition: Beta-thalassemia Major
Intervention: Genetic: LentiGlobin® BB305 Drug Product
4 Recruiting Study of ACE-536 to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia Intermedia
Condition: Beta-thalassemia.
Intervention: Drug: ACE-536
5 Recruiting Genetic Factors Affecting the Severity of Beta Thalassemia
Condition: Beta Thalassemia
Intervention:
6 Recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Intervention: Drug: SOTATERCEPT (ACE-011)
7 Unknown † Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia
Conditions: Sickle Cell Anemia;   Beta-Thalassemia;   Microalbuminuria
Intervention: Other: No intervention
8 Not yet recruiting Post Hematopoietic Stem Cell Transplantation
Condition: Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Intervention: Drug: ICL670
9 Not yet recruiting Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Condition: Thalassemia Major
Interventions: Biological: S-303 Treated Red Blood Cells (RBCs);   Biological: Conventional, untreated Red Blood Cells
10 Not yet recruiting An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
Condition: β-thalassemia Major
Intervention: Drug: Deferasirox
11 Recruiting Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
Conditions: Transfusional Iron Overload;   Beta-Thalassemia
Intervention: Drug: SPD602 (FBS0701, SSP-004184)
12 Recruiting ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Condition: Confirmed Diagnosis of ß-thalassemia Major
Intervention: Genetic: Autologous CD34+ cells transduced with TNS9.3.55
13 Not yet recruiting Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Conditions: Beta-thalassemia Major;   Sickle Cell Disease;   Iron Hemosiderosis
Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670);   Drug: DFP, DFO
14 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematological Malignancies;   Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders;   Hurler Syndrome (MPS I);   Krabbe Disease (Globoid Leukodystrophy);   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
15 Recruiting Stem Cell Transplant in Sickle Cell Disease and Thalassemia
Conditions: Sickle Cell Disease;   Beta Thalassemia
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
16 Not yet recruiting Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
Condition: Thalassemia Intermedia
Interventions: Drug: Hydroxyurea ,Epiao;   Drug: hydroxyurea, blood transfusion
17 Recruiting Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
Conditions: Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune(Registered Trademark));   Alemtuzumab (Campath(Registered Trademark))
Interventions: Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath(Registered Trademark));   Drug: Sirolimus (Rapamune(Registered Trademark));   Drug: Cyclophosphamide (Cytoxan(Registered Trademark));   Procedure: Low Dose Irradiation
18 Not yet recruiting The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
Condition: Thalassemia Major
Interventions: Drug: Vitamin D3;   Drug: Placebo
19 Recruiting High-Tc Susceptometer to Monitor Transfusional Iron Overload
Conditions: Transfusional Iron Overload;   Thalassemia Major;   Sickle Cell Disease;   Myelodysplastic Syndromes;   Aplastic Anemia
Intervention: Device: Hepatic biomagnetic susceptibility measurement
20 Recruiting Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Condition: Thalassemia Major With Severe Transfusional Iron Overload
Intervention: Drug: Deferasirox and deferiprone
To Top

Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results
† Indicates status has not been verified in more than two years